Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.60 – $6.99
0% from low
Exchange
OTC Link
CS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $2.3M | $24.9M | $4.30B | $1.03B | $345.2M | $824.9M | $1.03B |
| Cost of revenue | $113.6M | $147.5K | $13.8M | $1.30B | $1.22B | $1.22B | $244.4M | $350.2M |
| Gross profit | −$112.5M | $2.1M | $4.7M | $3.00B | −$186.6M | −$876.0M | $580.5M | $681.9M |
| Gross margin | -9939.4% | 93.5% | 19.0% | 69.8% | -18.1% | -253.8% | 70.4% | 66.1% |
| R&D | $113.6M | $151.7M | $428.5M | $878.7M | $778.3M | $638.0M | $416.1M | $230.5M |
| Operating income | −$138.6M | −$200.2M | −$397.8M | $1.94B | −$1.37B | −$2.04B | −$403.4M | −$113.1M |
| EBITDA | −$126.3M | −$204.9M | −$498.8M | $1.85B | −$1.32B | −$1.65B | −$109.8M | $61.0M |
| Net income | −$138.3M | −$156.8M | −$396.6M | $1.91B | −$909.4M | −$1.48B | −$378.9M | $27.2M |
| Net margin | -12215.6% | -6865.5% | -1593.6% | 44.5% | -88.2% | -429.6% | -45.9% | 2.6% |
| EPS (diluted) | -0.88 | -0.63 | -1.60 | 7.74 | -3.69 | -6.01 | -1.53 | 0.11 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.5B | $0.40 | $0.38–$0.43 | 1 |
| 2027 | $1.8B | $1.06 | $1.01–$1.13 | 1 |
| 2028 | $2.3B | $1.37 | $1.31–$1.46 | 1 |
| 2029 | $2.8B | $3.70 | $3.54–$3.95 | 1 |
Forward consensus · source: Financial Modeling Prep
CANSINO BIOLGICS REG H
No one on the platform currently holds CASBF.
No tracked institution reports a position in CASBF as of their last filing.
No one on the platform has traded CASBF yet.
| +5.09% |
| $2.7B |
| — |
| DMPHFDermapharm Holding SE | $53.00 | +0.00% | $2.6B | — |
| HTSUFHisamitsu Pharmaceutical Co., Inc. | $29.00 | +0.00% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.8× sales vs its 1.3× historical median P/S.
Fair value ≈ $4.56 · price $2.60 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.